Corbus Pharmaceuticals Holdings, Inc. Stock
Equities
CRBP
US21833P3010
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
42.87 USD | -0.28% | +10.43% | +609.77% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 3.33M | Capitalization | 450M |
---|---|---|---|---|---|
Net income 2024 * | -49M | Net income 2025 * | -69M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 135 x |
P/E ratio 2024 * |
-7.32
x | P/E ratio 2025 * |
-7.39
x | Employees | 19 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.32% |
Latest transcript on Corbus Pharmaceuticals Holdings, Inc.
1 day | -0.28% | ||
1 week | +10.43% | ||
Current month | +15.74% | ||
1 month | +4.94% | ||
3 months | +94.86% | ||
6 months | +1,256.65% | ||
Current year | +609.77% |
Managers | Title | Age | Since |
---|---|---|---|
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Sean Moran
DFI | Director of Finance/CFO | 66 | 14-04-10 |
Chief Tech/Sci/R&D Officer | 50 | Feb. 27 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Holmer
CHM | Chairman | 74 | 13-12-31 |
Avery Catlin
BRD | Director/Board Member | 75 | 14-07-31 |
Yuval Cohen
CEO | Chief Executive Officer | 49 | 13-06-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-13 | 42.87 | -0.28% | 151,972 |
24-05-10 | 42.99 | -1.71% | 92,145 |
24-05-09 | 43.74 | +3.18% | 650,385 |
24-05-08 | 42.39 | +6.59% | 779,421 |
24-05-07 | 39.77 | +2.45% | 160,195 |
Delayed Quote Nasdaq, May 13, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+609.77% | 452M | |
+5.66% | 109B | |
+11.23% | 105B | |
-0.38% | 22.25B | |
-12.15% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.09% | 16.85B | |
+3.33% | 13.76B | |
+36.58% | 12.46B |
- Stock Market
- Equities
- CRBP Stock